NHS opened a consultation on a new approach for annual updating the National Genomic Test Directory

03

Nov 2020

NHS England has opened a consultation on the proposed approach to updating the National Genomic Test Directory set out in the consultation document.

The National Genomic Test Directory (Test Directory) was established in 2018 within a new NHS Genomic Medicine Service (GMS) framework. Test Directory identifies the full range of genomic tests – from whole-genome sequencing (WGS) to tests for single genes and molecular markers – that are commissioned by the NHS in England. The Test Directory sets out the technology by which tests are available and the patients who will be eligible to access a test. The Test Directory was updated in 2019 and 2020 with minor changes.

The proposed new approach for the annual Test Directory update is summarized below.

  • Test Directory will be updated on an annual basis supported by the most up-to-date scientific, clinical, and economic evidence
  • Updates to the Test Directory will be overseen by the Genomics Clinical Reference Group (CRG) represented by professionals, patients, and public
  • Three test evaluation working groups will provide clinical and scientific support to the Genomics CRG and will cover rare disease, cancer, and pharmacogenomics
  • Updates to the Test Directory may be mandated in a year by the following policy decisions:
    • Medicines approval by Technology Apprisale program by the National Institute for Health and Care Excellence (NICE), where a genomic test forms part of the access criteria for a drug
    • Urgent policy statements issued by NHS Specialised Commissioning, where NHS England and NHS Improvement needs to urgently implement a commissioning policy involving genomic tests
    • Publication of NICE Diagnostics Assessment Programme (DAP) guidance
  • NHS England and NHS improvement will set aside a portion of its budget each year to pay for the implementation of new tests or implementing other changes to the Test Directory. The total funding envelope for updating the Test Directory will be determined on an annual basis, taking into account the spending from the previous and other spending commitments within the year
  • Applications for amendments to the Test Directory must be submitted to the NHS Genomics Unit (england.genomics@nhs.net) from January to April (to come into effect by April of the following year)
  • From April 2021 onwards, NHS England and NHS Improvement will follow the full approach and annual timescales to inform the update to the Test Directory to be published in April 2022

Stakeholders are invited to review the proposed approach and provide feedback on the following key topics

  • Appropriate involvement of patients and the public throughout the process
  • The proposed timelines for submission of applications
  • Any potential impact the proposal may have on health equalities.

Comments should be submitted through the consultation survey via the consultation hub till November 17, 2020.

See more information here

This news is just one of about 300 market access news collected by our team in the subscription services “HTA Alerts” and “Reimbursement Alerts” every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). First EU issues of both newsletters are available for download free-of-charge.

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks).

The latest related news

23

Mar 2022

In late January 2022, Swedish Medical Technologies Product (MTP) Council issued an updated version of recommendations regarding gene expression analysis for decision-making on the adjuvant breast cancer treatment, initially published in November 2021. The recommendation to the regions remains the same. The changes were only concerned with the clarification of some facts.

Read more

21

Mar 2022

The NHS Insights Prioritisation Programme (NIPP) is commissioned by the NHS Accelerated Access Collaborative (AAC) and the National Institute for Health Research (NIHR). It is designed to accelerate the evaluation and implementation of innovation that supports post-pandemic ways of working, builds service resilience, and delivers benefits to patients. Fourteen projects have been funded and have now commenced activity that will be ongoing until March 2023.

Read more

18

Mar 2022

On February 22, 2022, a repository of innovative acts outside the nomenclature of biology and anatomopathology (RIHN) and a Supplementary list of IVD tests were published. Minor changes were introduced in the 2022 RIHN list.

Read more

14

Mar 2022

In February 2021, the Clinical Coding and Schedule Development (CCSD) working group, which develops and maintains procedural and diagnostics nomenclature for private payers in England, published Bulletins 0182 and 0079 with changes to be implemented no later than April 10, 2022. Three new procedure codes concerned robotic surgery in orthopaedic area, spinal procedures, and ophthalmology, and five new diagnostic codes were introduced.

Read more

08

Mar 2022

At the end of February 2022, the Dental and Pharmaceutical Benefits Agency (TLV) has launched a theme survey on products for monitoring and diagnostics of sepsis to identify products that may be relevant for health economic assessments at TLV. The suggestions for the products of interest, ongoing clinical studies, or innovation projects could be received until 23 March 2022.

Read more